Hedgehog signaling in basal cell carcinoma

Journal of Dermatological Science

Volumn 78, Issue 2, 2015, Pages 95-100

  Otsuka, Atsushi ^a   Levesque, Mitchell P ^b   Dummer, Reinhard ^b   Kabashima, Kenji ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Acquired immune responses; Basal cell carcinoma; Hedgehog

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CYCLOPAMINE; GAMMA INTERFERON; GLASDEGIB; ITRACONAZOLE; JANUS KINASE; LEQ 506; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PATIDEGIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; RAPAMYCIN; S6 KINASE; S6 KINASE 1; SONIDEGIB; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VISMODEGIB; ANILIDE; CELL SURFACE RECEPTOR; G PROTEIN COUPLED RECEPTOR; PATCHED RECEPTORS; PYRIDINE DERIVATIVE; SMO PROTEIN, HUMAN; SONIC HEDGEHOG PROTEIN;

ANTIGEN PRESENTING CELL; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CANCER GROWTH; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CD8+ T LYMPHOCYTE; DISTANT METASTASIS; EMBRYONAL RHABDOMYOSARCOMA; ENZYME ACTIVATION; GAIN OF FUNCTION MUTATION; GENE SEQUENCE; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; LOSS OF FUNCTION MUTATION; MEDULLOBLASTOMA; MENINGIOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR MICROENVIRONMENT; UPREGULATION; ADAPTIVE IMMUNITY; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, BASAL CELL; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; SKIN NEOPLASMS;

ADAPTIVE IMMUNITY; ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; HEDGEHOG PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; PYRIDINES; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84927087950     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2015.02.007     Document Type: Review

References (45)

1. Lomas A., Leonardi-Bee J., Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012, 166:1069-1080.
2. Rubin A.I., Chen E.H., Ratner D. Basal-cell carcinoma. N Engl J Med 2005, 353:2262-2269.
3. Dreier J., Cheng P.F., Bogdan Alleman I., Gugger A., Hafner J., Tschopp A., et al. Basal cell carcinomas in a tertiary referral centre-a systematic analysis. Br J Dermatol 2014, 171:1066-1072.
4. Walling H.W., Fosko S.W., Geraminejad P.A., Whitaker D.C., Arpey C.J. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev. 2004, 23:389-402.
5. Arits A.H., Mosterd K., Essers B.A., Spoorenberg E., Sommer A., De Rooij M.J., et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013, 14:647-654.
6. Boaventura P., Pereira D., Mendes A., Batista R., da Silva A.F., Guimaraes I., et al. Mitochondrial D310 D-Loop instability and histological subtypes in radiation-induced cutaneous basal cell carcinomas. J Dermatol Sci 2014, 73:31-39.
7. Dreier J., Cheng P.F., Bogdan Alleman I., Gugger A., Hafner J., Tschopp A., et al. Basal cell carcinomas in a tertiary referral centre: a systematic analysis. Br J Dermatol 2014, 171:1066-1072.
8. Varjosalo M., Taipale J. Hedgehog: functions and mechanisms. Genes Dev 2008, 22:2454-2472.
9. Johnson R.L., Rothman A.L., Xie J., Goodrich L.V., Bare J.W., Bonifas J.M., et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996, 272:1668-1671.
10. Wong S.Y., Reiter J.F. The primary cilium at the crossroads of mammalian hedgehog signaling. Curr Top Dev Biol 2008, 85:225-260.
11. Amakye D., Jagani Z., Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med 2013, 19:1410-1422.
12. Hahn H., Wicking C., Zaphiropoulous P.G., Gailani M.R., Shanley S., Chidambaram A., et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996, 85:841-851.
13. Gorlin R.J. Nevoid basal cell carcinoma syndrome. Dermatol Clin 1995, 13:113-125.
14. Gailani M.R., Stahle-Backdahl M., Leffell D.J., Glynn M., Zaphiropoulos P.G., Pressman C., et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996, 14:78-81.
15. Xie J., Murone M., Luoh S.M., Ryan A., Gu Q., Zhang C., et al. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature 1998, 391:90-92.
16. Atwood S.X., Whitson R.J., Oro A.E. Advanced treatment for basal cell carcinomas. Cold Spring Harb Perspect Med 2014, 4:a013581.
17. Athar M., Li C., Kim A.L., Spiegelman V.S., Bickers D.R. Sonic hedgehog signaling in basal cell nevus syndrome. Cancer Res 2014, 74:4967-4975.
18. Nitzki F., Becker M., Frommhold A., Schulz-Schaeffer W., Hahn H. Patched knockout mouse models of basal cell carcinoma. J Skin Cancer 2012, 2012:907543.
19. Makino S., Masuya H., Ishijima J., Yada Y., Shiroishi T. A spontaneous mouse mutation, mesenchymal dysplasia (mes), is caused by a deletion of the most C-terminal cytoplasmic domain of patched (ptc). Dev Biol 2001, 239:95-106.
20. Hahn H., Wojnowski L., Zimmer A.M., Hall J., Miller G., Zimmer A: Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med 1998, 4:619-622.
21. Keeler R.F., Binns W. Teratogenic compounds of Veratrum californicum (Durand). I. Preparation and characterization of fractions and alkaloids for biologic testing. Can J Biochem 1966, 44:819-828.
22. Chiang C., Litingtung Y., Lee E., Young K.E., Corden J.L., Westphal H., et al. Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. Nature 1996, 383:407-413.
23. Dreier J., Dummer R., Felderer L., Nageli M., Gobbi S., Kunstfeld R. Emerging drugs and combination strategies for basal cell carcinoma. Expert Opin Emerg Drugs 2014, 19:353-365.
24. Liang M., Lv J., Chu H., Wang J., Chen X., Zhu X., et al. Vertical inhibition of PI3K/Akt/mTOR signaling demonstrates in vitro and in vivo anti-fibrotic activity. J Dermatol Sci 2014, 76:104-111.
25. Sekulic A., Migden M.R., Oro A.E., Dirix L., Lewis K.D., Hainsworth J.D., et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012, 366:2171-2179.
26. Gehrke S., Otsuka A., Huber R., Meier B., Kistowska M., Fenini G., et al. Metastatic melanoma cell lines do not secrete IL-1beta but promote IL-1beta production from macrophages. J Dermatol Sci 2014, 74:167-169.
27. Walter A., Barysch M.J., Behnke S., Dziunycz P., Schmid B., Ritter E., et al. Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas. Clin Cancer Res 2010, 16:3562-3570.
28. Fujiyama T., Oze I., Yagi H., Hashizume H., Matsuo K., Hino R., et al. Induction of cytotoxic T cells as a novel independent survival factor in malignant melanoma with percutaneous peptide immunization. J Dermatol Sci 2014, 75:43-48.
29. Kato Y., Yoshino I., Egusa C., Maeda T., Pili R., Tsuboi R. Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells. J Dermatol Sci 2014, 75:140-147.
30. Otsuka A., Dreier J., Cheng P.F., Nageli M., Lehmann H., Felderer L., et al. Hedgehog pathway inhibitors promote adaptive immune responses in Basal Cell Carcinoma. Clin Cancer Res 2015, PMID: 25593302.
31. Nomura T., Kabashima K., Miyachi Y. The panoply of alphabetaT cells in the skin. J Dermatol Sci 2014, 76:3-9.
32. Haniffa M., Gunawan M., Jardine L. Human skin dendritic cells in health and disease. J Dermatol Sci 2014.
33. Rowbotham N.J., Hager-Theodorides A.L., Cebecauer M., Shah D.K., Drakopoulou E., Dyson J., et al. Activation of the Hedgehog signaling pathway in T-lineage cells inhibits TCR repertoire selection in the thymus and peripheral T-cell activation. Blood 2007, 109:3757-3766.
34. Rowbotham N.J., Hager-Theodorides A.L., Furmanski A.L., Crompton T. A novel role for Hedgehog in T-cell receptor signaling: implications for development and immunity. Cell Cycle 2007, 6:2138-2142.
35. Rowbotham N.J., Furmanski A.L., Hager-Theodorides A.L., Ross S.E., Drakopoulou E., Koufaris C., et al. Repression of hedgehog signal transduction in T-lineage cells increases TCR-induced activation and proliferation. Cell Cycle 2008, 7:904-908.
36. Zhou F. Molecular mechanisms of IFN-γ to up-regulate MHC class I antigen processing and presentation. Int Rev Immunol 2009, 28:239-260.
37. Laner-Plamberger S., Wolff F., Kaser-Eichberger A., Swierczynski S., Hauser-Kronberger C., Frischauf A.M., et al. Hedgehog/GLI signaling activates suppressor of cytokine signaling 1 (SOCS1) in epidermal and neural tumor cells. PLoS ONE 2013, 8:e75317.
38. Ogawa Y., Kawamura T., Matsuzawa T., Aoki R., Shimada S. Recruitment of plasmacytoid dendritic cells to skin regulates treatment responsiveness of actinic keratosis to imiquimod. J Dermatol Sci 2014, 76:67-69.
39. Rodon J., Tawbi H.A., Thomas A.L., Stoller R.G., Turtschi C.P., Baselga J., et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res 2014, 20:1900-1909.
40. Munchhof M.J., Li Q., Shavnya A., Borzillo G.V., Boyden T.L., Jones C.S., et al. Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened. ACS Med Chem Lett 2012, 3:106-111.
41. Skvara H., Kalthoff F., Meingassner J.G., Wolff-Winiski B., Aschauer H., Kelleher J.F., et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol 2011, 131:1735-1744.
42. Lappano R., Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011, 10:47-60.
43. Tremblay M.R., Lescarbeau A., Grogan M.J., Tan E., Lin G., Austad B.C., et al. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem 2009, 52:4400-4418.
44. Kim J., Aftab B.T., Tang J.Y., Kim D., Lee A.H., Rezaee M., et al. Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 2013, 23:23-34.
45. Campbell S.B., Walker R., Tai S.S., Jiang Q., Russ G.R. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012, 12:1146-1156.